Agriculture and animal husbandry are a sea and a sky. The sea is vast and the sky is wide, and Kunpeng spreads its wings. The rapid development of agriculture and animal husbandry in the past nearly 40 years bears the glorious years of many elites striving for their ideals.
In the animal health industry, senior expert Zhang Yunkui is quite prestigious. He once served as the deputy director of the Animal Husbandry and Veterinary Research Institute of the Jiangxi Academy of Agricultural Sciences, the founder of MegaFenghua Biotechnology Group, and the senior vice president of Dabeinong Group.
has been riding the wave of trends for more than 40 years, from technological research, to application practice, to animal protection enterprise management. Adhering to science, facing challenges head-on, having the courage to make breakthroughs, and continuous learning have always been his unchanging creeds.
In 1992, Zhang Yunkui graduated with a master's degree from the College of Veterinary Medicine of China Agricultural University. He first worked in the management of a Sino-foreign joint venture chicken farm, combining theory with practice. He was then invited to return to the Institute of Animal Husbandry and Veterinary Medicine of the Jiangxi Academy of Agricultural Sciences as deputy director. And led the team to achieve a number of scientific research results.
In 1998, with the idea of learning from the advanced and catching up with the advanced, Zhang Yunkui entered a foreign-funded enterprise and absorbed advanced foreign science and technology, management concepts, service experience, operating models and innovation awareness. At the same time, he was also admitted to Peking University Guanghua School of Management to study for EMBA, where he systematically studied business management knowledge and theories.
2002 coincided with Dabeinong’s intention to expand into the animal health industry. Zhang Yunkui was moved by Dabeinong's corporate culture, sentiments, mission and vision, and inspired by the lofty mission of "serving the country and revitalizing agriculture", he immediately decided to join Dabeinong Group.
At Dabeinong Group, the research project "Porcine Circovirus Type 2 (DBN-SX07 Strain) Inactivated Vaccine" directed by Zhang Yunkui became a successful case in my country at that time for an enterprise to independently apply for a "New Veterinary Drug Registration Certificate". He also proposed and promoted live pseudorabies vaccine for intranasal immunity of piglets in China, and summarized and promoted the treatment of porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, swine mycoplasma pneumonia, swine fever, pseudorabies and other diseases that seriously damaged livestock production. Important disease prevention and control concepts for the economic benefit of the pig industry.
20 Years of unremitting struggle throughout the spring, summer, autumn and winter, accompanied by the continuous growth of Dabeinong’s animal vaccine business, Zhang Yuankui was not bound by his existing achievements, but chose to retire when he achieved success, leaving the stage to his successors.
The years are fleeting and time is like a song. The exploration of life and the world will not fade with the enrichment of resumes. After
retired, he felt more free and found it easier to find something he liked and that was meaningful to the industry.
In 2021, Jiangxi Bomeilai Biotechnology Co., Ltd. launched a new inactivated vaccine for porcine PRRS "Lantilai". This product may subvert the traditional understanding of PRRS inactivated vaccine and reshape the concept of immune purification of the disease.
With nearly forty years of industry experience, after several exchanges with Dr. Lin Xuye, chairman of Haitai Biotechnology, and his team, Zhang Yuankui believes that "Lantai Lai" should be a product that can solve the problem of blue-eared pigs in my country's pigs. Products that address the purification problem of disease should assist Dr. Lin Xuye’s team in promoting the concept of “immune purification of pig blue-ear disease”.
"Agricultural Treasures Collection" Xinmu.com: How did you get to know Jiangxi Bomeilai Biotechnology Co., Ltd.? Why are you optimistic about Jiangxi Bomeilai?
Zhang Yunkui: First of all, I must state that Dabeinong Group is an agricultural high-tech enterprise that is ideal for professional managers to find employment and start businesses. Here I would like to thank Dr. Shao Genhuo, chairman of the board of directors of Dabeinong Group, for his kindness. I am grateful that he gave me a huge career platform. I am grateful for his correct leadership and full support, which allowed me to strive in Dabeinong Group. In the spring, summer, autumn and winter of 20 years, my personal abilities have grown rapidly. At the same time, I would also like to thank my colleagues who have worked hard with me. It is their efforts and hard work that enabled Dabeinong’s animal vaccine business to develop from scratch, from small to large, into today’s Mega Biotech Group. .
If a person works for a company for a long time, he will gradually develop inertia, which is detrimental to the development of the company. In addition, I am approaching retirement age. In order not to affect the development of Dabeinong's vaccine business, I chose to retire early to see the outside world and do something that I like and that is helpful to the development of the industry.At this time, Jiangxi Bomeilai Biotechnology Co., Ltd., led by Dr. Lin Xuye, launched a new product - "Lantile". After several exchanges, it was felt that "Lantile" could inactivate PRRS. Vaccines are not simple. According to reports, this vaccine uses the world's leading genetic engineering technology, cell engineering technology, protein engineering technology, vaccine adjuvant technology and inspection and detection technology, and applies multiple invention patents, subverting the traditional understanding of PRRS inactivated vaccines. Knowledge, reshaping the concept of immune purification of diseases. With nearly 40 years of industry experience, I think it should be a vaccine that can solve the problem of blue ear disease, one of the major diseases that harms my country's pig industry.
However, today, when the theory and practice of prevention and control of pig PRRS are very confusing, it will undoubtedly be a huge challenge to successfully promote the concept of "using inactivated vaccine to purify PRRS". I sincerely admire Dr. Lin Xuye’s unique vision, strong will and courage to face difficulties, and I wish Jiangxi Bomeilai Company a better tomorrow.
"Agricultural Wealth Collection" Xinmu.com: What kind of enterprise is Jiangxi Bomeilai Company in your eyes? What history and culture is there?
Zhang Yunkui: Jiangxi Bomeilai Biotechnology Co., Ltd. was formerly known as Jiujiang Bomeilai Biological Products Co., Ltd. . It was established in 2005 and is affiliated to Jiangxi Bomeilai Pharmaceutical Factory. As a new company among the 28 biological products companies in my country, Jiangxi Bomeilai Company has developed very well since its establishment. It has more than 20 product production licenses and annual sales of tens of millions of yuan. After Haitai Company led by Dr. Lin Xuye invested in Jiangxi Bomeilai Company, it greatly improved the company's technical strength and social influence, and the quality and performance of its products have been greatly improved.
Affected by various factors such as the environmental crisis, the Sino-US trade war, African swine fever, and the new crown epidemic, the structure of my country's breeding industry has undergone tremendous changes. Large and extra-large breeding enterprises (groups) will become the main body of the breeding industry. The marketing model of animal health product companies serving breeding companies will inevitably undergo fundamental changes. It is understood that this year they will further improve the company's marketing organizational structure, directly face large and extra-large breeding enterprises, and provide breeding enterprises with more accurate and personalized products and services.
"Agricultural Treasures Collection" Xinmu.com: What is the current product structure of Jiangxi Bomeilai? Which leading products are currently performing well in the market?
Zhang Yunkui: Jiangxi Pomilai passed the new version of GMP acceptance of the Ministry of Agriculture in March 2021. The company has 7 production lines passing dynamic acceptance and 3 production lines passing static acceptance. The products cover pigs, poultry (including waterfowl), cattle and sheep and other animals. It is understood that Jiangxi Bomeilai's leading products for pigs include "Lan Tai Lai", "Yuan Tai Lai", "Smart Immunity Pack", "Animal Baotai", etc., and its leading products for poultry include "Qin Tai Lai", "Poultry Tai Lai" and "Poultry Tai Lai". Baotai" and so on.
Jiangxi Pomilai's CNAS also passed acceptance in March 2022, indicating that the company will continue to launch more competitive products with independent intellectual property rights.
"Agricultural Treasures Collection" Xinmu.com: In recent years, the animal health care product market has been rapidly introducing new products, and the application of new strains and new technologies has greatly affected the market structure. What are the technical advantages of BOMELAI?
Zhang Yunkui: The technical support of Bomeilai mainly comes from the R&D team of Guangzhou Haitai Biotechnology. The R&D team is led by Dr. Li Qichang, a Chinese-American scientist, and consists of more than 30 PhDs at home and abroad with rich practical experience in R&D. The team has joined forces with a large number of well-known domestic and foreign institutions of higher learning, including Cornell University in the United States, Oxford University in the United Kingdom, Hong Kong University of Science and Technology, Pingtung University of Science and Technology in Taiwan, Nanjing Agricultural University, Yangzhou University, Zhongkai Agricultural College, and the South China Sea Institute of Oceanography. Schools and scientific research institutes have established a strong platform for product research and development, achievement incubation, maturation and transformation, and have carried out extensive and in-depth technical cooperation.At present, a number of multi-linked multivalent vaccines based on genetic engineering technology have achieved breakthrough progress; the application of cell engineering technology and virus modification technology has greatly increased the vaccine antigen titer and improved the immune effect of the product; the new The application of adjuvant technology comprehensively improves the specific and non-specific disease-resistant immunity of vaccine-immunized animals. It is believed that in the near future, the company will have more high-quality and high-efficiency vaccines based on new strains and genetic engineering technology on the market.
"Agricultural Treasures Guide" Xinmu.com: Last year, Jiangxi Bomeilai Company launched the blue ear inactivated vaccine. What is its protective effect? How to break through the immunity barrier of blue ear inactivated vaccine?
Zhang Yunkui: In my country, blue-ear disease is the most harmful disease to the pig industry besides African swine fever. Under normal circumstances, there are two types of prevention and control measures for PRRS, one is closed group purification, and the other is vaccination. The vaccine is divided into live attenuated PRRS vaccine and inactivated PRRS vaccine. In fact, PRRS attenuated vaccines have different levels of residual virulence due to different degrees of attenuation. As we all know, PRRS is an immunosuppressive disease just like human AIDS. The stronger the residual virulence of the attenuated PRRS vaccine, the stronger the immune suppression caused by and . On the contrary, the weaker the immune suppression caused by it. In this regard, the commonly used attenuated PRRS vaccine has safety risks.
It is generally believed that the inactivated vaccine for PRRS is safe, but its effect is not satisfactory. To improve the immune protection rate of PRRS inactivated vaccine and solve its effectiveness problem, it is necessary to increase the effective antigen content in the vaccine, as well as the cellular immunity and humoral immunity of the vaccine.
In order to improve the virus titer, it is reported that they used cell cloning technology and virus cloning technology, and at the same time conducted targeted screening of the cell culture medium and serum used for cell culture.
What should be noted here is that the virus titer is not equal to the effective antigen content. To this end, they also used international advanced technology and technology to fully expose the antigenic sites on the virus particles. In this way, the virus titer can be directly proportional to the effective antigen content, thereby increasing the virus titer and thereby increasing the effective antigen content. Purpose.
In the body's immunity against PRRS, cellular immunity plays a more important role than humoral immunity. Cellular immunity plays an important role in clearing viruses within infected cells, and humoral immunity plays an important role in clearing viruses outside cells. Through repeated experiments, they screened out vaccine adjuvants with independent intellectual property rights, achieving the goal of simultaneously improving vaccine cellular immunity and humoral immunity.
Following this technical route, the technical barrier to immune effectiveness of the PRRS inactivated vaccine was broken, and an inactivated vaccine that accelerates the purification of PRRS in pigs - Lantaili was born. Not long after it was launched, more than 200 large and extra large-scale pig farms with different infection backgrounds of PRRS epidemic strains have been using Ratile. Farm directors, veterinarians and technical directors generally believe that Ratile has solved the problems they have faced for many years. The problem is that the viral load of infected pigs is declining, the neutralizing antibodies related to PRRS have always remained within a reasonable range, and the production performance of pig farms is getting better and better.
"Agricultural Treasures Collection" Xinmu.com: I heard that Jiangxi Bomeilai Company has established a cellular immunity evaluation standard. What significance does it have for the industry?
Zhang Yunkui: Due to the influence of detection methods and conditions, for a long time, the immune effect evaluation of vaccines has mostly used humoral immunity assessment methods such as ELISA, IHA, etc. that detect the negative and positive antibodies and the level of antibodies. In fact, these assessment methods are one-sided and inaccurate. To accurately evaluate the immune effect of the vaccine, it is also necessary to evaluate the cellular immunity after vaccine immunization. Cellular immunity assessment methods usually use flow cytometer , and flow cytometer equipment and reagents are very expensive. The body's immunity against PRRS mainly relies on cellular immunity, and cellular immunity must be measured to evaluate the immune effect of the inactivated PRRS vaccine.In order to solve this problem, Jiangxi Bomeilai Company has established an economical and practical cellular immunity detection method, that is, using the fluorescence quantitative PCR method to detect CD4+ T lymphocytes, CD8+ T lymphocytes , γ-interferon, etc., as well as immunosuppression Factors IL-10, TGF-β, etc.
The establishment of these methods not only reduces the cost of testing cellular immunity, but also enables a more comprehensive assessment of the immune effect of vaccines, effectively analyzing the body's immunity level and factors that may affect the body's immune function; the establishment of cellular immunity evaluation standards is of great importance. Further promoting the development of the animal health industry has extremely positive significance.
"Agricultural Treasures Collection" Xinmu.com: It is understood that Jiangxi Bomeilai Company has focused on building a research and development platform for subunit vaccine . Do they plan to launch multiple subunit vaccines such as swine fever E2 + ring Cap + pseudorabies subunit?
Zhang Yunkui: Using genetic engineering technology, natural or synthetic genetic material is inserted into bacteria, yeast or mammalian cells to fully express it. After purification, the subtype does not contain infectious substances. Unit vaccines, stable attenuated vaccines and multi-linked multivalent vaccines that can prevent a variety of diseases are the mainstream directions of vaccine research and development in the world. At present, the Guangzhou Hitech Biotechnology R&D team has mastered this type of technology, and can simultaneously express cellular immune mediating factors with excellent cellular immune effects on this type of vaccine, making the subunit vaccine both safe and excellent. The effects of humoral immunity and cellular immunity.
In addition, they have also mastered the technology of tightly linking multiple vaccines after expression, which is more conducive to the production of multi-linked multivalent subunit vaccines with good effects. This type of vaccine has strong market competitiveness and is likely to become the main direction for the continued development of Haitai Biological and Jiangxi Bomeilai Company. According to reports, the swine fever E2+circular Cap protein+pseudorabies subunit vaccine is just one of the multi-linked multivalent vaccines they are developing. Currently, multiple subunit vaccines or combination vaccines have completed the preliminary research and development and are preparing to enter the market. clinical application stage.
"Agricultural Treasures Collection" Xinmu.com: Some people believe that the next five years will be another turning point in the competition in the animal health market. What do you think will be the key to competition in the animal health industry in the next five years? What are the current main opportunities in the field of animal vaccines?
Zhang Yunkui: The key to competition in the animal health industry in the next five years lies in the convenience, economy and effectiveness of products. With the advancement of large-scale, intensive and intelligent breeding models, the methods and ways of using animal vaccine protection products should also change accordingly. The research and development direction must be the convenience of use, such as drinking water immunization, oral immunization, spray immunization, No-shot immunization, etc. The economy and effectiveness of animal vaccines must always be paid attention to, especially for food animals such as pigs and poultry, which have low unit prices. The economy of vaccines is always an issue that requires special attention.
The current development opportunities in the field of animal vaccines are mainly in the emerging important animal disease vaccines, bacterial disease vaccines, the use of modern high-tech to improve the immune effect of traditional vaccines, multi-linked multivalent vaccines based on genetic engineering, and some Several aspects including the prevention, control and inspection and testing products of emerging zoonotic infectious diseases .
"Agricultural Wealth Collection" Xinmu.com: The current pig industry is facing great challenges. As an upstream enterprise, it is also facing market pressure. How do you think Jiangxi Bomeilai should face the current unfavorable situation?
Zhang Yunkui: With the current slump in pig prices and skyrocketing prices of feed ingredients, the pig industry is facing huge challenges. As upstream enterprises in the breeding industry, they are also facing huge market pressure. Facing the severe situation, I believe that Jiangxi Bomeilai Company may adjust its existing product structure and concentrate on producing specialty products with obvious market advantages and more outstanding immune effects, such as their "Lantile" and "Yuantailai" , "Smart Immunity Kit" and other leading products, may also strengthen market research to provide customers with more precise services, such as providing serological testing and test report interpretation services, to carry out more convenient, more comprehensive and more accurate cellular immunity for customers Force Monitoring provides fluorescent quantitative PCR primers, etc.
Coordinator: Peng Jin
Reporter: Wang Zhixian
Source: Nongcaibandian Xinmu.com
